MyAlcon Professional Logo
Search for content Online Store
MyAlcon for Consumers

My Alcon | United States

This page is available in English. Select below for other locations.

Select another location

Accelerating the New
Glaucoma Paradigm 

Accelerating the New
Glaucoma Paradigm

Unlock first-line glaucoma care with Voyager™ DSLT

 

Consistent, precise treatment at the touch of a button.1

LEARN MORE
Image of DSLT

Hydrus® Microstent

 

The first and only MIGS device to report significant safety and effectiveness outcomes from a pivotal trial at 5 years.2,3

SEE MORE
Image of Hydrus Microstent
    REFERENCES:

    1. Voyager DSLT User Guide (US). [REF-26202].

    2. Ahmed IIK, et al. Long-term outcomes from the HORIZON randomized trial for Schlemm’s Canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-751.

    Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients. ClinTrials.gov (NCT01539239).

    ©2025 Alcon Inc. 01/25 US-DLT-2500017